Answers are grounded in this paper and cite their sources.
Introduction Tolvaptan has been approved for the treatment of autosomal dominant polycystic kidney disease (ADPKD). Nevertheless, an established therapeutic marker remains elusive. We evaluated the association between long-term urine osmolality trajectories and treatment outcomes in ADPKD patients treated with tolvaptan. Methods We included ADPKD patients who started tolvaptan between 2014 and 2022 and who had at least three years of follow-up. Patients were categorized into two groups according to changes in urine osmolality from baseline using a latent class trajectory model. We evaluated the associations of urine osmolality trajectories with kidney growth rate and eGFR decline. Results The analysis examined 57 patients, 49% female, with mean age of 51.7 ± 13.3 years, and mean total kidney volume of 1585.8 ± 1075.4 mL. Latent class trajectory analysis of urine osmolality over three years identified two classes: a larger-decrease class (class 1) and a milder-decrease class (class 2). Patients in class 1 had a significantly slower rate of eGFR decline than those in class 2 (-1.89 ± 0.15 vs. -2.70 ± 0.12 mL/min/1.73m2 per year, p<0.05). Multivariable regression analysis also revealed that class 1 was associated with a slower rate of eGFR decline. No significant association was observed between urine osmolality trajectory and kidney growth rate. Conclusion A larger decrease in urine osmolality, as identified by an unsupervised trajectory model, was associated with a slower rate of eGFR decline but not with the kidney growth rate. Urine osmolality trajectory may be a potential marker of treatment response to tolvaptan in ADPKD patients.
No takes yet. Share an insight, caveat, or question.
Morota et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: